Krystexxa Treatment

After your Krystexxa infusion, you may experience mild fatigue or tenderness at the IV site, which typically resolves within a few hours. Most patients can resume normal daily activities the same day. Our care team monitors you briefly after treatment to ensure you’re feeling well before discharge.
Over time, as uric acid levels drop, you may notice less joint pain, swelling, and fewer gout flares.

Many patients begin noticing improvements in pain, stiffness, and mobility within 4–6 weeks of starting therapy.
However, the exact timing can vary depending on your gout severity and how your body responds to treatment.
Regular follow-up blood tests will help your physician track uric acid levels and assess progress.

Krystexxa is generally well tolerated, but some patients may experience:

Mild infusion reactions (e.g., warmth, itching, or rash)

Temporary fatigue or nausea after treatment

Occasional gout flares as uric acid levels shift early in therapy

Our infusion staff monitors you closely throughout treatment and may provide premedications (like antihistamines or corticosteroids) to reduce side effects.
If you ever feel unwell during the infusion, we’re equipped to respond immediately.

Most major insurance plans, including Medicare and private providers, cover Krystexxa for patients who meet clinical criteria (chronic gout unresponsive to standard therapy).
Our administrative team will:

Verify your insurance benefits

Manage pre-authorization requests

Coordinate with your physician for medical documentation

We’ll guide you through the entire coverage process to make treatment as smooth and stress-free as possible.